BioXcel Therapeutics, Inc. beat EPS estimates 67% of the time across 3 reported quarters (2 beats, 1 misses). Data sourced from SEC EDGAR.
| Quarter | EPS Estimate | EPS Actual | Surprise | Result |
|---|---|---|---|---|
| Q22026 FY2026 | $-0.51 | $-0.49 | +3.9% | Beat |
| Q12026 FY2026 | $-0.59 | $-0.54 | +8.5% | Beat |
| Q42025 FY2025 | $-0.34 | $-0.58 | -70.6% | Miss |
Back to BTAI overview · BTAI holders · BTAI KPIs
Data sourced from U.S. SEC EDGAR filings. Not personalized investment advice.